# US 2009/0270328 A1 · Methods of increasing cerebral blood flow

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270328 A1
- Document ID: US20090270328A1
- Status: Published application
- Kind: A1
- Application number: 12/490,097
- Filed: 2009-06-23
- Published: 2009-10-29
- Earliest claimed: 2005-01-04
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Daria Mochly-Rosen; Rachel Bright
- Web page: https://patentgrep.com/patent/US20090270328A1

## CPC

- A61K 38/45: Transferases (2)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of δ protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided.

## Claims

### Claim 1

A method of treating an individual with a disease that causes decreased cerebral blood flow or an idiopathic cause that causes decreased cerebral blood flow, comprising administering a therapeutically effective amount of a peptide inhibitor of δ protein kinase C (δPKC), whereby said administering increases blood flow in a brain blood vessel.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said peptide is δV1-1 having an amino acid sequence set forth in SEQ ID NO:1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said peptide is δV1-1 having an amino acid sequence set forth in SEQ ID NO:1, δV1-2 having an amino acid sequence set forth in SEQ ID NO:2, δV1-5 having an amino acid sequence set forth in SEQ ID NO:3, or δV5 having an amino acid sequence set forth in SEQ ID NO:4.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said peptide has an amino acid sequence having at least about 95% identity to the amino acid sequence of δV1-1 set forth in SEQ ID NO:1, at least about 95% identity to the amino acid sequence of δV1-2 set forth in SEQ ID NO:2, at least about 95% identity to the amino acid sequence of δV1-5 set forth in SEQ ID NO:3, or at least about 95% identity to the amino acid sequence of δV5 set forth in SEQ ID NO:4.

### Claim 6 (depends on 1)

The method according to any one of claims 1, wherein said blood vessel is a cerebral artery, capillary, or arteriole.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said cerebral artery is an anterior cerebral artery, a middle cerebral artery or a posterior cerebral artery.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said peptide inhibitor is administered in an amount effective to increase blood flow at least about 10% relative to blood flow prior to administering said medicament.

### Claim 9 (depends on 7)

The method according to claim 7, wherein said peptide inhibitor is administered in an amount effective to increase blood flow at least about 50% relative to blood flow prior to administering said inhibitor.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said inhibitor of δPKC is conjugated to a carrier peptide.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said carrier peptide has the amino acid sequence set forth in SEQ ID NO:84 or SEQ ID NO:85.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said inhibitor is administered by a parenteral route.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said inhibitor is chronically administered without causing desensitization to said inhibitor.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said inhibitor is administered multiple times to a patient.

### Claim 15 (depends on 1)

The method of claim 1, wherein the disease is hypertension or wherein the individual has a vasoconstriction or vasospasm due to an idiopathic cause.

### Claim 16

A kit for increasing blood flow in a mammalian brain blood vessel in an individual with a disease that causes decreased cerebral blood flow or an idiopathic cause that causes decreased blood flow, comprising a peptide inhibitor of δPKC and instructions for using said inhibitor to increase blood flow in said blood vessel.

### Claim 17 (depends on 16)

The kit of claim 16, wherein said peptide is δV1-1 having an amino acid sequence set forth in SEQ ID NO:1.

### Claim 18 (depends on 16)

The kit of claim 16, wherein said peptide is δV1-1 having an amino acid sequence set forth in SEQ ID NO:1, δV1-2 having an amino acid sequence set forth in SEQ ID NO:2, δV1-5 having an amino acid sequence set forth in SEQ ID NO:3, δV5 having an amino acid sequence set forth in SEQ ID NO:4, or a combination thereof.

### Claim 19 (depends on 16)

The kit of claim 16, wherein said peptide has an amino acid sequence having at least about 95% identity to the amino acid sequence of δV1-1 set forth in SEQ ID NO:1, at least about 95% identity to the amino acid sequence of δV1-2 set forth in SEQ ID NO:2, at least about 95% identity to the amino acid sequence of δV1-5 set forth in SEQ ID NO:3, or at least about 95% identity to the amino acid sequence of δV5 set forth in SEQ ID NO:4.

### Claim 20 (depends on 16)

The kit of claim 16, wherein said inhibitor of δPKC is conjugated to a carrier peptide.
